Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.53), $0.12 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $4.55 million versus the consensus estimate of $13.4 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.